Yearly Archives: 2021


Agenus Announces Positive Preliminary Results of iNKT Cell Therapy Trial in COVID-19

LEXINGTON, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced positive preliminary results from its Phase 1 trial of iNKT cell therapy in patients with moderate to severe symptoms of COVID-19 through its subsidiary, AgenTus Therapeutics.

Read the original:
Agenus Announces Positive Preliminary Results of iNKT Cell Therapy Trial in COVID-19

ACTIVE BIOTECH ENTERS INTO A MANUFACTURING AGREEMENT WITH FAMAR HEALTH CARE SERVICES FOR NEW FORMULATION OF LAQUINIMOD

Active Biotech AB (publ) (NASDAQ STOCKHOLM: ACTI) today announced it has reached a manufacturing agreement with Famar Health Care Services Madrid SAU (“Famar”), a European provider of pharmaceutical manufacturing and development services. Famar will deliver clinical trial material of the newly developed eye-drop formulation of laqui­nimod.

View original post here:
ACTIVE BIOTECH ENTERS INTO A MANUFACTURING AGREEMENT WITH FAMAR HEALTH CARE SERVICES FOR NEW FORMULATION OF LAQUINIMOD

Alphageneron Pharmaceuticals Signed Exclusive License Agreement With Multimmune GmbH For Natural Killer Cell Platform Therapy Worldwide

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc., (Alphageneron) signed an Exclusive License Agreement with Multimmune GmbH, of Munich, Germany, (Multimmune) on October 1st, 2020, for its clinical stage autologous Natural Killer (“NK”) cell therapy and companion diagnostic platform, for all fields worldwide.

Read the original:
Alphageneron Pharmaceuticals Signed Exclusive License Agreement With Multimmune GmbH For Natural Killer Cell Platform Therapy Worldwide

EyePoint Pharmaceuticals Announces Closing of $115 Million Public Offering of Common Stock

WATERTOWN, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the closing of an underwritten public offering of 10,465,000 shares of its common stock at a public offering price of $11.00 per share, including the exercise in full by the underwriters of their option to purchase up to 1,365,000 additional shares of common stock. The gross proceeds of the offering to the Company are approximately $115.1 million, before deducting the underwriting discounts and commissions and other estimated offering expenses.

Read the rest here:
EyePoint Pharmaceuticals Announces Closing of $115 Million Public Offering of Common Stock

PRA Health Sciences to Report Fourth Quarter and Full Year 2020 Earnings

RALEIGH, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and full year 2020 results after the market closes on Thursday, February 25, 2021. The Company will also host a conference call on Friday, February 26, 2021 at 9:00 a.m. (ET) to discuss the results with members of the investment community.

Read more:
PRA Health Sciences to Report Fourth Quarter and Full Year 2020 Earnings

Stem Cells Market Value to Reach Around USD 17.79 Bn by 2027 – GlobeNewswire

February 04, 2021 08:57 ET | Source: Precedence Research

OTTAWA, Feb. 04, 2021 (GLOBE NEWSWIRE) -- The global stem cells market garnered revenue around USD 9.25 billion in 2019, according to new report study by Precedence Research.

Stem cells are also called as tissue specific and can renew themselves via mitotic cell division and differentiating into an assorted range of specialized cell type. Stem cells are found in all human being, from the early stages of human development to the end of life. Human body contains stem cells and may use it whenever required. These are used to develop the adult stem cells present in the body from the development of an embryo. Cord blood processing and storage together with automation in adult stem cell are the pointer technologies anticipated to positively impact the growth of the adult cord blood stem cells market. The existence of stem cell-based treatments has been established as a clinical standard of care for different conditions such as epithelial stem cell-based therapy for burns as well as corneal disorders and hematopoietic stem cell transplant for leukemia. The potential stem cell-based therapies have expanded owing to advances in stem cell-based research.

Get the Sample Pages of Report for More Understanding@ https://www.precedenceresearch.com/sample/1118

Growth factors

Since past few years, stem cells market is growing with the increasing investment in stem cell-based research by biopharmaceutical and pharmaceutical firm along with the success of regenerative medicines. Stem cells market is growth is backed by escalating number of clinical trials across the world. Some of the major factors driving the growth of the stem cells market include advancement in stem cell manufacturing technology as well as increasing harvest awareness regarding therapeutic potency. High occurrences of infections have steered the development of vaccines using various human diploid and non-tumorigenic cell lines.

Growing demands as well as awareness along with ongoing research and development of vaccines against different diseases are certain growth influencers of the stem cells market. Additionally, prevalence of chronic diseases will also fuel the market growth. Presence of advanced stem cells banking and availability of stem cells donor will significantly boost the market demand during upcoming years. Rigorous support of government via different initiatives aids stem cells banking to obtain significance. Increasing number of stem cells banks in emerging economies is further encouraging market penetration. Also, growing awareness about stem cell harvest which holds high potential in therapeutic and diagnosis field offers lucrative prospects to the market during impending years.

Intensifying prevalence of cancer worldwide is offering substantial boost to the growth of cancer stem cells market. As per the data published by World Health Organization, the global cancer implication is projected to have risen to around 18 million latest cases and around 9.2 million deaths in year 2018. Additionally, according to Cancer Research UK, the population enduring the cancer is anticipated to grow in near future.

Get Customization on this Research Report@ https://www.precedenceresearch.com/customization/1118

Report Highlights

Regional Snapshot

North America held the largest share in the market and is anticipated to continue its dominance over the forecast period due to existence of organized and developed healthcare systems which uplift research and development in the U.S. and Canada. Asia Pacific is likely to grow with the highest Compound Annual Growth Rate (CAGR) owing to wide usage of stem cells in regenerative medicines particularly in the sector of dermatology. Oncology applications are expected to grow at highest CAGR owing to large number of pipeline products available for the cure of cancer and tumors. Growing number of regenerative medicines centers are in turn expected to drive the stem cell in near future.

Related Reports

Key Players & Strategies

Stem Cells market is highly competitive and includes several major players such as STEMCELL Technologies, Inc., Osiris therapeutics, Inc., Cynata Therapeutics, Human Longevity, Inc., Advanced Cell Technology, Inc., BIOTIME, Inc.Mesoblast Limited, Promethera Biosciences S.A. N.V., Merck Group, Takara Bio Group. Prominent market giants are emphasizing on product development and improvement which is increasing overall competition in the market.

In January 2019, The Cesca Therapeutics acquired ThermoGenesis Corp., and formed new wholly-owned ThermoGenesis subsidiary in order to focus on its Car-TXpress cellular processing platform. This acquisition was directed at commercializing and developing automated technologies as well as medical devices integrated in the therapies.

Market Segmentation

By Product

By Application

By Technology

By Therapy

By Regional Outlook

Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/1118

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 774 402 6168

About Us

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

For Latest Update Follow Us:

https://www.linkedin.com/company/precedence-research/

https://www.facebook.com/precedenceresearch/

See the original post here:
Stem Cells Market Value to Reach Around USD 17.79 Bn by 2027 - GlobeNewswire